What is known and objective: This study used electronic medical records to identify risk factors and establish a detection algorithm for denosumab-induced hypocalcaemia.
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IMATOH eT Al.
| WHAT IS K NOWN AND OBJEC TIVE
Bone metastasis is a major complication in patients with cancer.
Approximately 70% of patients with breast or prostate cancer develop bone metastases. 1 Complications, including skeletal-related events (SREs), lead to severe pain and decreased the quality of life.
2
Bisphosphonates, including pamidronate, clodronate and zoledronate, have previously been shown to be effective for the treatment of bone metastases. Denosumab is a relatively novel, fully humanized monoclonal antibody directed against the receptor activator of nuclear factor kappa B ligand (RANKL), which mediates the formation, function and survival of osteoclasts. 3 Denosumab was found to be superior to zoledronic acid in prolonging the time to first on-treatment SRE in 2046 patients with breast cancer 4 
and in 1904
patients with castration-resistant prostate cancer. 5 The overall safety profiles of denosumab and zoledronic acid have been shown to be generally similar; however, hypocalcaemia has been found to occur more frequently in patients treated with the former than in those treated with the latter. 6 As fatal hypocalcaemic episodes associated with denosumab have been reported as the drug became available on the market in Japan, a Dear
Healthcare Professional Letter of Rapid Safety Communication was released in September 2012, along with revision of the denosumab package insert, including a precautionary statement regarding frequent serum calcium monitoring before administration of denosumab, prescription of oral supplementation of calcium and vitamin D, and so on. 7 Meanwhile, several studies concerning denosumab-induced hypocalcaemia have been conducted. The previous studies have revealed incidence rates of denosumab-induced hypocalcaemia ranging from 10% to 40%. The definitions have not been entirely consistent. There are limited data regarding the risk factors for denosumab-induced hypercalcemia.
Therefore, the aim of this study was to develop a detection algorithm and identify the risk factors for denosumab-induced hypercalcaemia using electronic medical health records.
| ME THODS

| Data source
Our data were obtained from a medical information database (MID) developed at Hamamatsu University Hospital (Shizuoka, Japan), which was called D*D. The MID was established based on a standardized structured medical information exchange system (SS-MIX). 8, 9 The MID F I G U R E 1 Flow chart of study process has been used for 16 years to store all prescription orders, laboratory examination results and data regarding disease classifications. The database contains more than 100 million records.
| Ethics
The study was approved by both the ethical review boards of 
| Development of detection algorithm
The study process is illustrated in Figure 1 . Hypocalcaemia was defined as a corrected serum calcium level of ≤2.13 mmol/L based on the guidelines for the differential diagnosis of hypocalcaemia compiled by the Japan Endocrine Society. 10 As ionized calcium levels
were not measured routinely, we used serum total calcium levels.
If albumin levels were below 40 g/L, calcium levels were corrected using the Payne formula, 11 as follows:
Corrected serum calcium level (mg/dL) = total serum calcium level (mg/dL) − serum albumin (g/dL) + 4.
The normal range of corrected serum calcium level is
A definitive diagnosis of denosumab-induced hypocalcaemia was made by two physicians through a review of patient medical records.
In cases in which the opinions of the reviewers differed, the diagnosis was made following consultation between the two physician reviewers.
| Identification of risk factors
A retrospective cohort study was conducted, and the following fac- Table S1 .
We also conducted a sensitivity analysis using another MID, provided by Medical Data Vision (MDV) Co., Ltd., covering about one of every six Japanese people. The flow chart of patient selection for sensitivity analysis is illustrated in Figure S1 .
| Statistical methods
All analyses were performed using R for Windows version 3. Receiver operating characteristic (ROC) curve analysis was used to estimate the optimal cut-off values of potential screening factors.
We obtained the optimal cut-off point of potential screening factors using the function "optimalcutpoints" in the "OptimalCutpoints" R package. Multiple logistic regression analysis was used to calculate the odds ratios (ORs) for denosumab-induced hypocalcaemia.
A P value of <0.05 was considered to indicate statistically significant difference.
| RE SULTS
| Development of the detection algorithm for denosumab-induced hypocalcaemia
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| Risk factors for denosumab-induced hypocalcaemia
A retrospective cohort study was conducted to evaluate the potential risk factors for denosumab-induced hypocalcaemia. A total of 16 patients diagnosed with definitive denosumab-induced hypocalcaemia were defined as cases, and another 144 patients who were administered denosumab were defined as controls. Table 1 shows the baseline characteristics of patients in the case and control groups. A statistically significant difference was observed between the groups in the proportion of serum ALP levels >5.95 μkat/L prior to initial prescription (P < 0.01). Other patient characteristics did not significantly differ between the two groups. In the sensitivity analysis, 88 patients (23.5%) were suspected to have denosumab-induced hypocalcaemia. There were significant differences in sex, the proportion of other cancers and the proportion of serum ALP levels >5.95 μkat/L prior to initial prescription (sex: P < 0.01, other cancer:
P < 0.05, serum ALP levels >5.95 μkat/L prior to initial prescription:
We estimated the ORs of the potential risk factors using logistic regression analysis ( 
| D ISCUSS I ON
We conducted a pharmacoepidemiological study to elucidate the detection algorithm and identify the risk factors for denosumab-induced hypocalcaemia using an electronic MID. Our findings revealed that the mean and median values of time to onset of hypocalcaemia in patients with denosumab-induced hypocalcaemia were shorter than those in patients with non-denosumab-induced hypocalcaemia.
Hence, we used the time to onset of hypocalcaemia as the second screening factor. The estimated optimal cut-off point was 90 days, with a PPV of 87.5%. A study conducted by Body et al 13 Our results are largely consistent with the findings of the previously mentioned studies.
Next, we investigated the risk factors for denosumab-induced hypocalcaemia. Our findings revealed that an elevated serum ALP level before initial denosumab prescription was associated with hypocalcaemia. The same findings were observed even though we used another electronic MID. Kinoshita et al 15 reported that patients with higher serum ALP levels at baseline had a higher risk of developing hypocalcaemia. A large retrospective cohort study by Body et al 13 suggested that higher bone-specific ALP levels at baseline are a risk factor for hypocalcaemia. On the other hand, several previous studies have suggested an association between renal dysfunction and increased risk of denosumab-induced hypocalcaemia. 14, 16 However, the efficacy and safety of denosumab in patients with decreased kidney function, including those undergoing haemodialysis, have been confirmed. [17] [18] [19] Jamal et al 18 concluded that denosumab was not associated with an increase in adverse events among patients with impaired renal function. In addition, the association between serum ALP levels and hypocalcaemia was not evaluated in the above-mentioned studies. As renal failure is a known risk factor for hypocalcaemia, renal failure per se may increase the risk of hypocalcaemia regardless of denosumab prescription.
In adults with healthy liver function, approximately 50% of total serum ALP activity is derived from bone. 20 ALP is a marker of osteoblast differentiation and bone formation. Osteoblasts express RANKL on the extracellular surface of osteoclasts. As a result, denosumab may induce hypocalcaemia by excess RANKL inhibition.
Hence, elevated serum ALP levels may be a predictor for the development of hypocalcaemia.
The present study has some limitations. First, as the data were collected retrospectively, certain confounding factors were not analysed. In addition, the bone-specific ALP was not routinely measured. Therefore, we could not evaluate the association be- Patients with high serum calcium levels were strictly diagnosed by two physicians. However, the kappa index was 0.49. Although the misclassification of patient outcome can occur, the misclassification is nondifferential. Almost all patients had received calcium replacement therapy at the time of initial denosumab prescription.
Although calcium replacement therapy may not affect the development of hypocalcaemia, our study may nonetheless underestimate the incidence of denosumab-induced hypocalcaemia. Thus, further investigations are needed to validate our findings.
In summary, we developed a novel detection algorithm for denosumab-induced hypocalcaemia using an electronic MID. Our algorithm comprised serum calcium levels and time from initial denosumab prescription to the onset of hypocalcaemia, and this algorithm was superior to an algorithm based only on serum calcium levels. Moreover, we found that an elevated total serum ALP level was a risk factor for denosumab-induced hypocalcaemia in patients prescribed denosumab.
Clinicians should carefully monitor patients' initial serum calcium levels and screen for signs of hypocalcaemia in patients receiving denosumab who demonstrate elevated serum ALP levels.
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